Polymorphonuclear leukocytes (PMN) have been identified as cells capable of producing a number of pro-and antiinflammatory cytokines in response to specific agonists. Previously, we showed that tumor necrosis factor (TNF), interleukin-lB (IL-I~, and IL-8, are produced by PMN after stimulation with agonists, such as lipopolysaccharide (LPS). In this study, we demonstrate that LPS is also a potent stimulus for the mRNA expression and release of the IL-1 receptor antagonist (IL-lra). In addition, we show that the release of IL-lra from LPS-stimulated PMN is markedly potentiated in the presence of IL-10 (from two to threefold after 18 h of stimulation). Moreover, we observed that this upregulation of IL-lra production by IL-10 in LPS-stimulated PMN took place through IL-lra mRNA stabilization. Indeed, the half-life of IL-lra mRNA was prolonged in PMN stimulated in the presence of IL-10 and LPS, as compared with cells stimulated with LPS alone. That IL-10 selectively upregulates IL-lra production in LPS-activated PMN, while it inhibits the production of IL-13, TNF, and IL-8 under the same conditions, suggests that IL-10 may be an important physiologic regulator of cytokine production from PMN, and emphasizes the potential role of IL-IO in inflammatory responses.
p
MN are specialized effector cells involved in acute inflammatory responses. For instance, PMN mediate antimicrobial defense and antitumoral activity through the release of toxic oxygen intermediates or lytic enzymes (1) . In addition, several studies have shown that PMN have the ability to produce many different cytokines known to play an important role in inflammatory and immune responses, including TNF, IL-1, and IL-8 (reviewed in reference 2). More recently, it has been reported that the gene expression and production of the IL-1 receptor antagonist (IL-lra) can be stimulated in human neutrophils (3) (4) (5) . IL-lra is a 23-to 25-kD glycosylated protein, originally purified from supernatants of human monocytes cultured on immune complex-coated surfaces (6) , or from the urine of patients with monocytic leukemia (7) , which has been recently cloned (8, 9) . While IL-lra competes with both IL-lot and IL-13 for binding to the IL-1 receptor (7), it does not initiate internalization of the receptor-ligand complex, or transduce an activation signal (10) .
Although IL-lra has generated considerable interest based on its ability to block the proinflammatory activities of IL-1 in vivo (11, 12) , the regulation of IL-lra expression in human PMN remains poorly understood. Since IL-10, a molecule known for its immunosuppressive properties (13), was previously shown to modulate TNF, IL-13, and IL-8 cytokine gene expression and production in PMN (14) , we examined the effect of IL-10 on neutrophil-derived IL-lra release. We now report that in human PMN, the release of IL-lra was potently induced by LPS, and that IL-10 significantly upregulated LPS-elicited IL-lra production. These findings suggest that IL-10, by favoring the production of IL-lra by PMN over that of IL-1 (14) , may exert potent antiinflammatory effects on host responses to gram-negative infections.
Materials and Methods
Cell Purification and Culture. Highly purified (>99.5%) PMN were isolated under endotoxin-free conditions from buffy coats of healthy donors, as previously described (14, 15) . Immediately after purification, PMN were suspended in RPMI 1640 medium supplemented with 10% low endotoxin FCS (<0.006 ng/ml; Irvine Scientific, Santa Ana, CA), in the presence or absence of purified recombinant human IL-10 (protein concentration, 50 #g/ml; sp act, 2 x 107 U/mg; kindly provided by Dr. K. Moore, DNAX and Schering-Plough Corporation, Palo Alto, CA). Cells were then stimulated with 1/~g/ml LPS (from Escherichia coli 026:B6, purchased from Sigma Chemical Co., St. Louis, MO) and cultured at 37~ either in 24-well tissue culture plates (Nunc, Roskilde, Denmark) at 106 cells/300/~1, or in polystyrene flasks (Greiner, Nurtingen, Germany) at 5 x 106 cells/ml (14) . Cell-free supernatants were harvested at various time points, spun at 2,000 rpm for 30 s, and stored at -70~ before IL-lra determination. All reagents were of highest grade and were dissolved in pyrogen-free water for clinical use (15) .
RNA Isolation and Northern Blot Analyses. Extraction and
Northern blot analysis of total RNA from PMN were performed as already described (14, 15) . The cDNA fragment for ILlra (which was a gift from Dr. A. Mantovani, Mario Negri Institute, Milano, Italy), as well as the cDNA fragments for ILS, IL-1/~, heavy chain subunit of cytochrome bsss (gp91-phox), and actin, were 32p. labeled using a Ready-to-go DNA labeling kit (Pharmacia LKB, Uppsala, Sweden), before hybridization of nylon filters and autoradiography.
Detection oflL-lra. Extracellular ILlra was determined using a specific ELISA kit (50 pg/ml detection limit) purchased from Amersham International (Little Chalfort, UK).
Statistical Analyses.
Where mentioned, data were assessed for statistical significance using Student's t test for paired data. Data are expressed as means + SEM.
Results

Effect of lL-lO on IL-lra Production in LPS-stimulated PMN.
Purified populations of PMN were preincubated for 30 min with optimal doses of IL-10 (100 U/ml) (14) , and cultured for up to 18 h in the presence or absence of LPS. Fig. 1 shows that the release of IL-lra protein into the culture supernatants of unstimulated PMN (4, 5) was not significantly affected by the presence of IL-10. In contrast, PMN stimulation with LPS resulted in a substantial release of IL-lra protein that began as early as after 2 h and increased progressively with time ( Fig. 1) . Moreover, IL-10 treatment greatly potentiated the secretion of IL-lra protein in LPS-stimulated PMN ( Fig.  1 ). This enhancing effect of IL-10 was significant after 6 h of LPS stimulation, and a maximal effect of IL-10 was observed at 18 h. Similar results were obtained when PMN were exposed to as little as 10 ng/ml LPS (not shown).
Effect of lL-lO on IL-Ira mRNA Expression in PMN Stimulated with LPS.
We next determined whether IL-10 exerted its enhancing effect on LPS-stimulated IL-lra release at the level of m R N A . Northern blot analyses were performed on total R N A isolated from PMN preincubated with IL-10, and stimulated for different times in the presence or the absence of LPS. As shown in Fig. 2 , resting PMN expressed low levels of IL-lra transcripts, which were not influenced by the pres- lation after 2 h. At later time points, however, the amounts of IL-lra m R N A transcripts were maintained at high levels in IL-10-treated PMN, whereas under the same conditions, the LPS-induced accumulation of IL-8 m R N A was suppressed by IL-10 pretreatment (14) , while that ofgp91-phox m R N A was not influenced by the cytokine (Fig. 2) .
IL-IO Decreases Turnover of Message for IL-lra, but not that oflL-l~.
In an attempt to elucidate the mechanism whereby IL-10 could affect the accumulation of IL-lra transcripts in LPS-treated PMN, we examined the influence of IL-10 on cytokine mRNA stability. PMN were stimulated with LPS for 3.5 h, in the presence or absence of IL-10, and then treated with actinomycin D to block the formation of additional transcripts. At increasing intervals thereafter, the cultures were processed for Northern blot analysis, and changes in the amount of cytokine mRNA were quantitated by laser densitometric scanning. Whereas preliminary experiments had established that LPS stimulation (3 h) does not significantly alter IL-lra and IL-13 mRNA stability (not shown), Fig.  3 shows that IL-IO pretreatment markedly prolonged IL-lra mRNA half-life relative to diluent-treated cells, after 3.5 h of LPS stimulation (180 vs. 54 min, respectively). A similar effect of IL-10 on the turnover rate of IL-lra transcripts was exerted in cells stimulated with LPS for 5 h, a time point at which the differences in IL-lra mRNA levels were more evident (not shown). IL-10 did not significantly affect the stability of IL-I~ and actin mRNAs isolated from LPS-treated PMN (Fig. 3) .
Discussion
IL-1 is widely viewed as an important proinflammatory mediator and is thought to play a crucial role in a number of pathophysiological conditions (17). The actions of IL-1 can be controlled in several ways, such as by the regulation of its synthesis (18) , by the release of soluble IL-1 receptors (19, 20) , or by the production of IL-lra, an antagonistic inhibitor that blocks IL-1 binding to its receptor (6, 7) , thereby effectively preventing the biological actions of IL-1 (17). To date, studies addressing the expression of IL-lra in human PMN remain scarce. It has been reported, for instance, that the expression of IL-lra occurred only after neutrophil treatment with GM-CSF or TNF, but not with LPS, even if used over a 24-h period and at concentrations ranging from subto superoptimal levels (5). In contrast, other investigators have found that PMN have the ability to express IL-lra mRNA and protein in response to LPS (100/xg/ml) (4). In the same study, it was also demonstrated that, after intratracheal injection of LPS in the rat, substantial amounts of IL-lra mRNA were present in PMN-rich bronchoalveolar lavage (4). More recently, Re et al. (21) showed that concentrations of 1-10 ng/ml LPS were suf~cient to induce IL-lra expression in PMN. Our data are therefore consistent with the findings of the latter two reports, as well as with preliminary observations form our laboratory, that indicate that LPS represents an important stimulus for the expression of IL-lra in PMN, as it is more potent than IgG-opsonized yeast particles, or TNF-o~ (Cassatella, M. A., unpublished observations).
IL-IO is a product of various cell types including monocytes and lymphocytes (13) , that potently inhibits monocyte/macrophage function including proinflammatory cytokine release, oxidative burst, and nitric oxide production (22) (23) (24) , and that contributes to the regulation of lymphocyte proliferation and differentiation (13) . We have recently demonstrated that IL-10 can also act upon PMN function by specifically suppressing the LPS-induced release of TNF-ol, IL-13, and IL-8 by LPS-stimulated neutrophils (14) . In the present report we show that IL-10 markedly enhances the production of IL-lra in PMN stimulated with LPS. Further investigation of this effect of IL-10 revealed that whereas the cytokine substantially increased the half-life of IL-lra transcripts, it failed to modulate IL-13 mRNA stability, thereby demonstrating that the posttranscriptional actions of IL-10 are restricted to selected, LPS-inducible cytokine mRNA species. Consistent with our findings, it has been recently reported that the suppression by IL-10 of TNF and IL-1 mRNA accumulation in LPS-stimulated murine macrophages depended on de novo protein synthesis, and was not attributable to inhibition of TNF or IL-1 gene transcription rate (25), a conclusion that supports an action of IL-IO on posttranscriptional events. Although many cytokine mRNA species (e.g., TNF, IL-13, IL-8) contain all AU-rich sequences in their Yuntranslated regions that are believed to be involved in the regulation of mRNA stability (26) , these AU-rich motifs are Figure 3 . Effect of IL-10 on the turnover rate of IL-lra and 1I:1/3 mRNAs in LPS-stimulated PMN. PMN were cultured with 1/~g/ml LPS, in the presence or absence of IL-10. After 3.5 h, the cells were treated with actinomycin D (5/zg/ml) for an additional 4 h. (A) PMN were harvested at the indicated times, and total RNA was prepared and analyzed by Northern blotting using IL-lra, IL-13, and actin cDNA probes. (B) RNA bands were analyzed densitometrically, the data were plotted on semilogarithmic graphs as percent remaining mR.NA vs. time decays in min, and the resulting values plotted against time. Halflives were calculated by regression analysis. One representative experiment out of four performed is shown. not present in IL-lra mRNA (8, 9) . Thus, it appears that IL-lra mRNA stability may be regulated by IL-10 in a unique manner. It is, for example, possible that IL-10 reduces the expression of a nuclease that selectively degrades IL-lra mRNA, or that induces/increases the expression of a factor that decreases the susceptibility of IL-lra mRNA to the action of such a nuclease. In this respect, Bogdan et al. (25) postulated the possible existence of nucleolytic activities controlling TNF and IL-1 mRNA expression, which IL-10 could modulate. In any case, other effects of IL-10 at the level of PMN transcription, translation or secretion cannot be excluded.
The ability of IL-10 to upregulate IL-lra production in PMN may reflect one of the mechanisms underlying the immunosuppressive actions of IL-10 (13), and in particular could contribute to the ef~cacy of IL-10 in downregulating LPS toxicity in vivo (27, 28) . Very recently, mouse mutants were generated in which the IL-10 gene was inactivated by targeted mutation (29) . As these IL-10-deficient mice suffered predominantly from chronic enterocolitis (29) , it was proposed that their primary defect was a failure to control normal intestinal immune responses against undefined enteric antigens, which led to an overproduction of proinflammatory cytokines, presumably by macrophages (29) . On the basis of the present data, and of our previous study (14) , it appears that one of the net effects of IL-10 toward neutrophils is to neutralize IL-1, both by inhibiting IL-1 production and by promoting the synthesis and secretion of its antagonist. Considering that in their initial phases, bowel inflammation diseases are also characterized by a massive infiltration of neutrophils (30) , the importance of the PMN as a source of cytokines under those circumstances must not be underestimated.
